496775-61-2

Storage:-20

Biologieal

Eltrombopag (rINN, codenamed SB-497115-GR) is a medication that has been developed for conditions that lead to thrombocytopenia (abnormally low platelet counts). It is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals

Reference

GlaxoSmithKline (2008-11-20). "FDA approves Promacta (eltrombopag), the first oral medication to increase platelet production for people with serious blood disorder". Press release. http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10127.htm. Retrieved 2008-11-25. ^ Jenkins JM, Williams D, Deng Y, et al. (2007). "Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist". Blood 109 (11): 4739�C41. doi:10.1182/blood-2006-11-057968. PMID 17327409. http://bloodjournal.hematologylibrary.org/cgi/content/full/109/11/4739.